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Abstract
Background: No biomarker exists to guide the optimal choice of chemotherapy for patients with metastatic
colorectal cancer. We examined the copy numbers (CN) of topoisomerase I (TOP1) as well as the ratios of TOP1/
CEN-20 and TOP1/CEN-2 as biomarkers for irinotecan efficacy in patients with metastatic colorectal cancer.
Methods: From a national cohort, we identified 163 patients treated every third week with irinotecan 350 mg/m2
as second-line therapy. Among these 108 were eligible for analyses and thus entered the study. Primary tumors
samples were collected and tissue microarray (TMA) blocks were produced. FISH analysis was performed using two
probe-mixes: TOP1/CEN-20 and TOP1/CEN-2. Only samples harboring all three signals (TOP1, CEN-20 and CEN-2)
using FISH were included in the analyses.
Results: In the TOP1/CEN-20 probe-mix the median TOP1- and CEN-20 CN were 4.46 (range: 1.5–9.5) and 2.00
(range: 0.55–4.55), respectively. The median TOP1- and CEN-2 CN in the TOP1/CEN-2 probe-mix, were 4.57 (range: 1.
82–10.43) and 1.98 (range: 1.22–6.14), respectively. The median TOP1/CEN-20 ratio and TOP1/CEN-2 ratio were 1.25
(range: 0.92–2.90) and 2.05 (range: 1.00–6.00), respectively. None of the markers TOP1 CN, TOP1/CEN-20-ratio or
TOP1/CEN-2-ratio were associated with progression free survival, overall survival or baseline characteristics. Yet, we
observed a borderline association for a stepwise increase of the TOP1 CN in relation to objective response as hazard
ratio were 1.35 (95% CI 0.96–1.90; p = 0.081).
Conclusions: We verified a borderline significant association between increasing TOP1 CN and objective response
as previously reported. Applying the probes representing CEN-20 and CEN-2, in order to investigate the ratios of
TOP1/CEN-20 and TOP1/CEN-2 provided no further information in search of a biomarker driven patient stratification.
Other biomarkers to be paired with TOP1 CN are therefore highly warranted.
Keywords: Biomarker, Colorectal cancer, FISH, Gene copy number, Irinotecan, Topoisomerase I
Background
Colorectal cancer (CRC) is the third most common cancer
and the fourth most common cause of cancer death world-
wide [1]. Almost 50% of patients diagnosed with CRC will
develop metastatic disease [2]. Standard of care for patients
with non-resectable metastatic colorectal cancer (mCRC) is
combination chemotherapy with 5-fluorouracil (5-FU)/
leucovorin (LV)/oxaliplatin (FOLFOX) or 5-FU/LV/irinote-
can (FOLFIRI) with or without a targeted agent [3]. In first-
line therapy, FOLFIRI and FOLFOX are considered equally
effective [4].
Predictive biomarkers for the efficacy of 5-FU, irinote-
can and oxaliplatin have been suggested but none, so far,
have been implemented in the clinical setting [5]. How-
ever, a significant fraction of the patients does not bene-
fit from the treatment but may experience serious side
effects only. The topoisomerase 1 (Top1) protein is an
essential nuclear enzyme for vital cellular processes such
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as DNA replication, transcription, translation, recombin-
ation and repair. The primary function of Top1 is to un-
wind and uncoil the supercoiled DNA double helix by
transiently cleaving one of the two strands and thereby
allowing its rotation over the other strand [6]. This
intermediate cleavage state is termed the Top1 cleavage
complex (Top1cc). Top1 is the target of irinotecan
(CPT-11), a camptothecin derivative, which is metabo-
lized to the active metabolite SN-38 which binds to and
stabilizes the Top1cc, whereby the rapidly moving DNA
replication and transcription complexes collide with this
trapped Top1ccs. The main cytotoxicity induced by iri-
notecan is caused by DNA double-strand breaks during
DNA replication and the presence of Top1 is thus a pre-
requisite for this cytotoxic effect [7, 8].
The plausible link between tumor tissue levels of Top1
and effect of Top1 inhibitors in cancer treatment [9] has
been investigated by different methods. In vitro studies
with colon cancer cell lines have demonstrated a signifi-
cant correlation between the topoisomerase I gene
(TOP1) copy numbers (CN) or Top1 protein expression
and the sensitivity to SN-38 [9, 10]. A prospective clin-
ical trial (FOCUS) investigated the association between
Top1 protein expression and benefit from FOLFOX and
FOLFIRI in patients with mCRC [11]. A significant asso-
ciation between Top1 protein immunoreactivity and
clinical benefit from FOLFIRI or FOLFOX was found.
However, conflicting results have been reported since
the findings could not be validated in a subsequent study
from the same group (FOCUS3) [12]. Furthermore, the
results from another large prospective trial (CAIRO)
showed no correlation of Top1 immunoreactivity and
response to irinotecan in patients with mCRC [13]. An
explanation to these diverse results was recently pro-
vided by (Maughan et al.) who showed that the antibody
used for IHC in the above mentioned studies did not
result in reproducible staining patterns [12]. We have
recently introduced another approach for Top1 quanti-
tation in cancer cells. Instead of immunohistochemistry
IHC to quantitate protein expression we used fluores-
cence in situ hybridization (FISH) to assess TOP1 gene
copy number (CN) status as a proxy for the overall
Top1 protein levels. We have previously identified a sig-
nificant correlation between the TOP1 gene CN, TOP1
mRNA expression and Top1 protein levels using data
generated from in vitro studies on CRC cell lines [14].
The (TOP1) gene is located on chromosome 20 at
20q12 and this region frequently undergoes CN alter-
ations in various cancers [14–17]. In CRC, the TOP1
aberration has been reported by applying a TOP1/CEN-
20 fluorescence in situ hybridization (FISH) probe-mix.
The TOP1 CN gain in CRC has been reported to be in
the range of 53–84%, whereas TOP1/CEN-20 ratios ≥ 1.5
or ≥2.0 were in the range of 30–40% and 10–20%,
respectively [14, 18, 19]. Current data suggests that
TOP1 CN increases occur predominately in conjunction
with the rest of 20q [14, 16, 17, 20] and the CEN-20 re-
gion [14, 18]. Therefore the usage of the TOP1/CEN-20
ratio may underestimate the genuine TOP1 amplifications.
Chromosome 2 (CEN-2) has been found to be the least af-
fected by independent numeric aberrations in the genome,
and has therefore been combined with TOP1 in a TOP1/
CEN-2 probe-mix to distinguish between TOP1 gene gain
and genuine TOP1 amplifications [21]. These two different
types of CN alterations have been demonstrated to have
differential prognostic effects in stage III CRC patients
[21]. In a metastatic setting a borderline significant associ-
ation (p = 0.07) between an increase in TOP1 CN and ob-
jective response to second-line treatment with irinotecan
monotherapy has been reported [19].
Therefore, we applied both a TOP1/CEN-20 and a
TOP1/CEN-2 FISH probe-mix to 108 tumors from
mCRC with the aim to investigate TOP1 CN and the ra-
tios of both TOP1/CEN-20 and TOP1/CEN-2 as bio-
markers for irinotecan efficacy.
Methods
The patients included in this explorative study were ex-
tracted from a national cohort of 498 patients with mCRC
who all received irinotecan in combination with the epi-
dermal growth factor receptor inhibitor, cetuximab as
third-line treatment from 1st of January 2005 to 1st of
August 2008 at the Departments of Oncology at Herlev,
Odense, and Aalborg Hospitals in Denmark. The inclusion
period for the national cohort was specifically selected be-
cause it preceded the introduction of KRAS testing.
Therefore, mutational status for KRAS, NRAS and BRAF
is unknown in this cohort. From this cohort we identified
163 consecutive patients who were treated every third
week with irinotecan 350 mg/m2 as second-line therapy.
Disease evaluation was performed during treatment using
computed tomography (CT) scans of the thorax and ab-
domen every 9–12 weeks to evaluate response according
to the RECIST 1.0 criteria [22]. Data for objective re-
sponse, progression-free survival (PFS) and overall sur-
vival (OS) were extracted from the database. PFS was
defined as time from start of treatment to progression or
death from any cause. OS was defined as time from start
of treatment to death from any cause. Last follow-up on
survival was done in October 2014. The study was ap-
proved by the Research Ethics Committee of Copenhagen
(H-KA-20060094). Reporting of the results was prepared
according to the REMARK criteria [23].
Tumor material
Only primary tumor samples were used. Formalin-fixed
paraffin-embedded samples from either resections or
core needle biopsies were collected. The presence of
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tumor cells in the samples was confirmed by a patho-
logic review performed by JP and an experienced gastro-
intestinal pathologist (DL). Tissue microarray (TMA)
blocks were produced; each containing tumor material
from 18 patients with two 1 mm tissue cores per patient
sample. Standard procedures were used for preparation
of the TMA blocks. The TMA blocks were cut in 2-μm
sections and stored at 5 °C until hybridization.
Fluorescence in situ hybridization (FISH)
The probes for TOP1, CEN-20 and CEN-2 were developed
and produced by the Department of Pathology, Herlev
University Hospital. All probes were sequenced to confirm
that all base pairs exactly matched the TOP1 gene and the
centromeres CEN-20 and CEN-2. Two probe-mixes:
TOP1/CEN-20 and TOP1/CEN-2 were produced. The
probes were labelled with Texas red (TOP1) and fluorescein
isothiocyanate (FITC), green for CEN-20 and CEN-2. Only
samples harboring all three signals (TOP1, CEN-20 and
CEN-2) using FISH were included in the analyses. Since
the TOP1 probe was present in both probe-mixes, it was
counted twice - independently.
Two slides from each TMA block were deparaffinized,
rehydrated, boiled in pre-treatment buffer for 10 min
and cooled in the buffer for 15 min at room temperature
followed by 2 × 3 min in wash buffer (1:20) (K5799 -
Dako). RTU-pepsin was added for 2 min at 37 °C and re-
moved in wash buffer for 2 × 3 min. Following ethanol
(70%→ 96%→ 99%) dehydration and 15 min. air-dry,
10 μL of TOP1/CEN-20 probe was applied to the center
of one of the two slides and 10 μL of TOP1/CEN-2
probe-mix was applied to the other slide. Non-specific
binding of probe was removed by stringency wash (1:20)
at 65 °C for 10 min (K5731 - Dako). A fluorescence
microscope (Olympus BX61) with DAPI, FITC, Texas
Red and dual FITC/Texas Red filter was used for
visualization of the signals. Signal counting was per-
formed by JP, blinded to all patient data. In case of ambi-
guity, a senior pathologist (DL) was consulted. A
minimum of sixty TOP1 signals in total, 30 from each of
the two cores, were counted in non-overlapping cancer
nuclei with well-defined morphology and distinct fluor-
escent signals. If the fluorescent intensity was weak or
insufficient tumor tissue was present, a new section was
cut. If signals continued to be too weak for clear inter-
pretation, the sample was excluded from the analyses.
Cutoffs and Definitions
A cutoff of 2 for the ratios of TOP1/CEN-20 and TOP1/
CEN-2 were used in this study.
Tumors were classified as “amplified” when (TOP1/
CEN-20 ratio ≥2 and TOP1/CEN-2 ratio ≥2) and as
“polysomies” when (TOP1/CEN-20 ratio ≤2 and TOP1/
CEN-2 ratio ≥2).
Statistics
To examine the association between TOP1 CN from the
two probe-mixes, a Reliability Analysis with an Intraclass
Fig. 1 CONSORT diagram showing the flow of patients and samples
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correlation was performed. Pearson’s chi-squared test was
used to test for associations between baseline characteris-
tics and TOP1 CN and TOP1-/CEN-20- and CEN-2 ra-
tios. The baseline characteristics were: gender, age, WHO
performance status (PS), location of primary tumor, resec-
tion of primary tumor, number of metastatic sites, prior
chemo- and radiotherapy, and presence of lung or liver
metastases. The TOP1 CN per cell was divided by the me-
dian value into two groups. TOP1/CEN-20- and CEN-2
ratios were divided into ≥2 and <2. p-values and 95% con-
fidence intervals (CI) are reported.
The final analyses of survival data were performed in
October 2014. Cox proportional hazards (CPH) regression
models were used to test for association between time-to-
event endpoints and both a dichotomized value and a con-
tinuous value of TOP1 signal count, TOP1/CEN-20 ratio,
and TOP1/CEN-2 ratio, with adjustment for baseline
characteristics. We also used CPH models to test “ampli-
fied” (TOP1/CEN-20 ratio ≥2 and TOP1/CEN-2 ratio ≥2)
vs “non- amplified” tumors and “polysomies” (TOP1/
CEN-20 ratio ≤2 and TOP1/CEN-2 ratio ≥2) vs “non-poly-
somies”. Wald chi-squared p-values hazard ratio (HR) es-
timates with estimated 95% CI interval were reported.
The association between TOP1 CN, TOP1/CEN-20
ratio, and TOP1/CEN-2 ratio and objective response rate
was tested using logistic regression. Responders were de-
fined as patients with complete (CR) or partial response
(PR) according to RECIST 1.0 criteria. We also performed
the same analysis using clinical benefit rate (CBR). Clinical
benefit was defined as CR, PR or stable disease (SD)
≥6 months. For these tests, Wald chi-squared p-values
and odds ratio (OR) estimates with 95% CI were reported.
Results
In the database of our national cohort, we searched for pa-
tients having received irinotecan monotherapy as second-
line therapy. We identified 163 patients. Of the 163, 26
(16%) patients were excluded as they did not have enough
tissue available for analyses, in 22 (13%) we failed to pro-
duce countable FISH signals from both probe-mix (TOP1/
CEN-20 and TOP1/CEN-2) after two attempts and 7
patients were not assessable for response due to either
concurrent surgery or radiotherapy. Thus, 108 patients
were eligible for analyses in the study (Fig. 1).
Fig. 2 Distribution of TOP1, CEN-20 and CEN-2 copy numbers and of TOP1/CEN-20 and TOP1/CEN-2 ratios. Distribution in colorectal cancer samples determined
by FISH. a Showing the distribution of the copy numbers for probe-mix TOP1/CEN-20. b Showing the distribution of the copy numbers for probe-mix TOP1/CEN-2
Table 1 Distribution of TOP1 CN and ratios for the 108 patients
TOP1 CN
No (%)
TOP1/CEN-2
ratio No (%)
TOP1/CEN-20
ratio No (%)
<2 7 (6) 50 (46) 98 (91)
2.0 – 2.99 23 (21) 36 (33) 10 (9)
3.0 – 3.99 14 (13) 18 (17) -
4.0 – 4.99 25 (23) 3 (3) -
5.0 – 5.99 15 (14) - -
6.0 – 6.99 13 (12) 1 (1) -
>7 11 (10) - -
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TOP1 CN was counted twice due to the use of two
probe-mixes. When comparing the results of TOP1 CN
from the two probe-mixes, the Single Measures Intra-
class correlation was r = 0.74 (CI 0.64–0.82; p <0.001).
The Spearman correlation between TOP1 and CEN-2
was: r = 0.44 (p <0.001), between TOP1 and CEN-20:
r = 0.82 (p <0.001) and between CEN-2 and CEN-20:
r = 0.41 (p <0.001).
For the TOP1/CEN-20 probe-mix, the median
TOP1- and CEN-20 CN were 4.46 (range: 1.5–9.5)
and 2.00 (range: 0.55–4.55), respectively. The median
TOP1- and CEN-2 CN in the TOP1/CEN-2 probe-
mix, were 4.57 (range: 1.82–10.43) and 1.98 (range:
1.22–6.14), respectively. The median TOP1/CEN-20
ratio and TOP1/CEN-2 ratio were 1.25 (range: 0.92–
2.90) and 2.05 (range: 1.00–6.00), respectively (Fig. 2).
The distribution of TOP1 CN and ratios for the 108
patients are shown in Table 1. We used the median
TOP1 CN (probe-mix TOP1/CEN-20) to test the as-
sociation with baseline characteristics (Table 2). Sig-
nificant associations between prior chemotherapy and
TOP1/CEN-2 ratio and between liver metastases and
TOP1/CEN-20 ratio were found. However, these re-
sults were not significant after correction for multiple
testing (data not shown).
Ten patients (9%) had PR, 46 (43%) had SD, and 51
(47%) had PD as best response. The distribution of
TOP1 CN for patients having PR, SD and PD is illus-
trated in Fig. 3. The OR estimates for a stepwise increase
of the TOP1 CN and TOP1/CEN-20 and TOP1/CEN-2
ratios in relation to objective response were 1.35 (CI
0.96–1.90; p = 0.081), 1.99 (CI 0.51–7.75; p = 0.32), and
1.34 (CI 0.69–2.64; p = 0.40), respectively. No significant
association was found between CBR and a stepwise
increase of the TOP1 CN, TOP1/CEN-20- or TOP1/
CEN-2-ratio as the OR estimates were 1.01 (CI 0.81–
1.25; p = 0.94), 0.72 (CI 0.24–2.14; p = 0.56), and 0.88 (CI
0.54–1.42; p = 0.60), respectively.
The median PFS and OS were 3.8 months (range: 1.3–
13.1) and 16.4 months (range: 4.6–91.6), respectively. None
of the biomarkers TOP1 CN, TOP1/CEN-20-ratio or
TOP1/CEN-2-ratio when tested as continuous variables,
were associated with PFS as HRs were 0.99 (CI 0.90–1.10;
p = 0.88), 0.99 (CI 0.56–1.74; p = 0.97), and 1.10 (CI 0.85–
1.35; p = 0.58), respectively. For OS, HRs were 0.98 (CI
0.89–1.08; p = 0.72), 1.02 (CI 0.61–1.70; p = 0.95), and 1.00
(CI 0.79–1.27; p = 0.98) for TOP1 CN, TOP1/CEN-20-ratio
and TOP1/CEN-2-ratio, respectively (Table 3).
We did not find any associations between the dichoto-
mized version of TOP1 CN and PFS and OS as HRs
were 0.95 (CI 0.65–1.40; p = 0.79) and 0.92 (CI 0.62–
1.35; p = 0.66), respectively. We also tested PFS as a
function of TOP1 CN divided into tertiles and found no
significant association, log-rank p = 0.66 (Fig. 4).
According to the definitions used, 9% had an ampli-
fied tumor (TOP1/CEN-20 ratio ≥ 2 and TOP1/CEN-2
ratio ≥ 2), 44% had a tumor harboring a q-20 polysomy
(TOP1/CEN-20 ratio ≤ 2 and TOP1/CEN-2 ratio ≥ 2),
and 46% had a tumor that was neither amplified nor a
polysomy. Patients with tumors classified as harboring
a TOP1 amplification did not have improved PFS: HR
1.71 (CI 0.88–3.32; p = 0.12) or OS: HR 1.32 (CI 0.69–
2.54; p = 0.41). Neither did patients with tumors classi-
fied as harboring q-20 TOP1 polysomy: PFS HR 0.94
(CI 0.64–1.38; p = 0.75) and OS HR 0.71 (CI 0.48–1.05;
p = 0.08). There were no significant associations be-
tween TOP1 amplification or q-20 TOP1 polysomy and
objective response.
No multivariate analysis was performed since the vari-
ables tested were not significant in the univariate
analyses.
Discussion
This study is the first to report the CN of TOP1 and the
ratios of TOP1/CEN-20 and TOP1/CEN-2 in CRC pa-
tients and their relation to objective response to irinote-
can in a metastatic setting. We added a probe for CEN-2
to discriminate between an increase in TOP1 CN due to
mechanisms localized to chromosome 20 and an in-
crease caused by increased ploidy level. We chose
chromosome 2 because this chromosome has been re-
ported to undergo fewer alterations when compared to
other chromosomes in cancer specimens [24]. In accord-
ance with this, a recent study investigating TOP1 CN ab-
errations, considered CEN-20 CN as an inappropriate
Fig. 3 Boxplot. Distribution of TOP1 copy number as a function of
best response to chemotherapy. The top and bottom of the box
represents the upper and lower quartiles and the black line in the
box the median. The whiskers represent the maximum and
minimum values, excluding outliers
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marker for cellular ploidy based on the frequent gain of
chromosome 20 or 20q [21].
TOP1 cut-off values were chosen based on the median
value. This decision was partly based on the results from
a similar study [25] and partly to obtain two equally
sized groups. In our study, we found a higher median
gene CN for TOP1 (4.46) than reported in the study by
Nygaard et al. (3.6) [25]. A plausible explanation for this
discrepancy could be the difference in number of cells
counted. In our study we counted a minimum of 60 sig-
nals of TOP1 CN for each patient giving a median of
14.5 and a range of 8–40 counted nuclei. This is less
than the 60 nuclei counted by Nygaard et al. One could
argue that since we selected the nuclei with the best
quality signals for counting we also tended to select the
nuclei with the highest CNs. Despite the difference in
methods, our study showed the same results as Nygaard
et al. concerning the association with objective response,
PFS, and OS.
Previously, a positive correlation between the TOP1
CN and in vitro sensitivity to SN-38 was reported in
CRC cell lines and this was also demonstrated for the
TOP1/CEN-20 ratio. Notably, the correlation for the
TOP1 CN was superior to the TOP1/CEN-20 ratio,
which is consistent with the data in our study [18]. Our
results demonstrated a borderline significant association
Table 3 Univariate survival analyses
Progression-free survival Overall survival
HR 95% CI p HR 95% CI p
Gender Females (ref) (ref) 0.03
Males 0.65 0.43–0.96 0.03 0.64 0.43–0.94
Age Per 1 year increase 0.99 0.97–1.02 0.63 0.98 0.96–1.01 0.16
WHO PS 0 0.84 0.57–1.24 0.38 0.59 0.39–0.88 0.009
1–2 (ref) (ref)
unknowna
Location primary tumor Right 0.74 0.45–1.23 0.25 1.21 0.72–2.02 0.48
Left 0.87 0.57–1.35 0.54 1.14 0.74–1.76 0.55
Rectum (ref) (ref)
Primary tumor resected Yes 0.78 0.41–1.51 0.46 0.78 0.40–1.50 0.49
No (ref) (ref)
Number of metastatic sites 1 (ref) (ref)
2 1.05 0.66–1.67 0.84 1.31 0.82–2.10 0.27
>2 1.23 0.77–1.96 0.40 1.51 0.95–2.40 0.09
Prior chemotherapy F (ref) (ref)
F + Oxa 0.99 0.52–1.92 0.99 2.50 1.25–5.00 0.009
F + Oxa + Bev 1.91 0.52–6.96 0.33 3.53 0.94–13.2 0.06
Prior radiotherapy Yes 0.71 0.29–1.75 0.46 0.85 0.35–2.10 0.73
No (ref) (ref)
Liver metastases Yes 0.88 0.57–1.37 0.58 1.18 0.76–1.82 0.64
No (ref) (ref)
Lung metastases Yes 1.09 0.73–1.61 0.67 1.50 1.01–2.21 0.044
No (ref) (ref)
TOP1 CN (CEN-20) Per 1 unit increase 0.99 0.90–1.10 0.88 0.98 0.89–1.08 0.72
TOP1 CN (CEN-20) >median (4.46) 0.95 0.65–1.40 0.79 0.92 0.62–1.35 0.66
≤ median (4,46) (ref) (ref)
TOP1/CEN-20 ratio Per 1 unit increase 0.99 0.56–1.74 0.97 1.02 0.61–1.70 0.95
TOP1/CEN-2 ratio Per 1 unit increase 1.10 0.85–1.35 0.58 1.00 0.79–1.27 0.98
TOP1/CEN-20 ratio <1.5 (ref)
≥1.5 0.73 0.47–1.13 0.16 0.75 0.48–1.17 0.21
Abbreviations: F Fluorouracil (5-FU), Oxa Oxaliplatin, Bev Bevacizumab, HR Hazard ratio, CI Confidence interval
aUnknowns were not included in the shown proportions or test for distribution differences
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between TOP1 CN and objective response (p = 0.08),
which is in accordance with the results by Nygaard et al.
(p = 0.07) [19]. However, this result was not further sup-
ported as there were no association between TOP1 CN
and PFS. Regarding the ratios of TOP1/CEN-20 or
TOP1/CEN-2 and response to irinotecan we found no
associations to irinotecan response. However, the TOP1
CNs was significantly correlated to the CEN-20 CNs
which may mask TOP1 amplification. Collectively, these
findings could support the use of gene CN only instead
of a gene/CEN ratio, which is further supported from
the clinically implemented human epidermal receptor-2
(HER2) FISH analysis where only HER-2 CN can be re-
ported without the ratio in cases with coamplification of
HER-2 and CEN-17 [26].
The patients in this study constituted a selected group
with a good prognosis as they were identified from a na-
tional cohort characterized by all patients having re-
ceived third line treatment (irinotecan + cetuximab).
Besides a long median OS (16.4 months) as could be ex-
pected in this selected group, the clinical data in this
study corresponded to what have previously been re-
ported from studies including irinotecan second-line
monotherapy with RR of 10% [27]. With 108 patients
and RR of only 9% we have limited power to detect a
predictive value of TOP1 as a biomarker for response.
For that reason, we also investigated clinical benefit rate.
A major obstacle for obtaining a high level of evidence
for predictive biomarkers is the lack of well-defined cut-
off values for overexpression and gene amplification.
Even for a well-established biomarker such as HER-2 in
breast cancer, cut-off values are still discussed and have
changed over time.
The level of Top1 protein expression could be use-
ful as a predictive biomarker for the response to
Top1 targeting chemotherapy. A number of studies
have investigated this possibility in patients having
CRC, but with conflicting results [10–14]. These in-
consistent results may partly be explained by the fact
that immunohistochemistry (IHC) requires validated
antibodies as well as standardized protocols, both of
which have been difficult to obtain for Top1. Accord-
ingly, Top1 IHC has not yet reached the required
level for clinical implementation.
Another aspect is the different DNA repair mecha-
nisms activated upon DNA damage which may in part
explain why TOP1 CN alone could not predict response.
A study reported that the expression of aprataxin, a his-
tidine triad domain superfamily protein involved in
DNA repair, in 30 CRC cell lines was correlated with
sensitivity to irinotecan [28]. Another repair pathway,
the tyrosyl-DNA-phosphodiesterase I (TDP1) was inves-
tigated in clinical CRC samples and cell lines. The au-
thors reported that TDP1 is involved in the resolution of
DNA damage associated with Top1 poisons and that the
protein expression levels of TDP1 or Top 1 alone were
not associated with sensitivity to irinotecan [29].
A robust correlation between TOP1 CN status, gene
expression level, protein expression level and -activity in
cancer cell lines [9, 30] and cancer tissues [31, 32] has
been reported. Accordingly, the TOP1 CN may be a use-
ful “proxy” predictive biomarker for Top1 targeting
drugs. One concern in this study is whether the TOP1
CN determined in primary tumors correspond to the
CN in the treated metastases. In our study primary tu-
mors were analyzed in order to test our hypothesis.
However, the majority of the treated tumor volumes in
these patients consisted of metastases. Conflicting re-
sults have been reported regarding the concordance be-
tween primary tumor and metastases. Two studies
reported a significantly higher Top1 expression in the
metastases than in the corresponding primary tumor
[33] [34]. Yet, other studies investigating TOP1 mRNA
[35] and Top1 protein levels [36] have reported con-
cordance between primary tumors and metastases. An-
other concern is the impact of prior treatments as it
may change the biologic profile between the primary
and recurrent tumors. An ideal design to overcome the
difficulties mentioned above would be to assess TOP1
CN in the metastasis from mCRC prior to first-line
irinotecan-containing therapy.
Conclusions
We verified a borderline significant association between
increasing TOP1 CN and objective response to irinote-
can monotherapy in mCRC patients as previously
reported. Applying CEN-20 and CEN-2, to TOP1, did
not provide further information to assist a biomarker
driven patient stratification, suggesting that other bio-
markers should be paired with TOP1 CN.
Fig. 4 Kaplan-Meier plot for progression-free survival as a function
of TOP1 gene copy number. Patients were divided into tertiles by
TOP1 copy number
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